Table 5.
Five-year survival.
| Squamous cell | Adenocarcinoma | Neuroendocrine | P-value 1 | ||||
|---|---|---|---|---|---|---|---|
| 5-year survival | (95% CI) | 5-year survival | (95% CI) | 5-year survival | (95% CI) | ||
| Stage IA (1A1, 1A2) | 96.4% | (95.8%–97.0%) | 98.2% | (97.2%–98.9%) | 81.8% | (44.7%–95.1%) | 0.02 |
| Stage IB (1B1, IB2, IB) | 80.4% | (79.7%–81.0%) | 85.7% | (84.7%–86.6%) | 55.4% | (49.3%–61.2%) | <0.001 |
| IIB | 57.2% | (56.2%–58.2%) | 51.2% | (48.3%–54.1%) | 22.2% | (14.1%–31.4%) | <0.001 |
| IIIB | 43.3% | (42.3%–44.2%) | 39.4% | (36.6%–42.1%) | 24.4% | (18.8%–30.4%) | <0.001 |
| IVA | 20.0% | (18.1%–22.0%) | 13.3% | (9.0%–18.5%) | 4.1% | (0.3%–17.5%) | 0.12 |
| IVB | 13.3% | (12.1%–14.5%) | 12.3% | (10.1%–14.8%) | 7.1% | (4.3%–10.9%) | <0.001 |
1
P-value was from log-rank test.